Developing a new class of safer, more effective mTOR inhibitors to extend human healthspan

mTOR inhibitors are the best-validated longevity therapeutics

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). mTOR inhibitors are an exceptionally well-explored therapeutic class, encompassing three FDA-approved medications evaluated in more than 3,000 clinical trials. Recent studies have demonstrated that mTOR inhibitors extend health and life span in multiple organisms, including yeast, worms, flies, and mice, establishing them as the best validated class of longevity therapeutics.

See press release

Tornado is developing safer, more effective mTOR inhibitors to extend human healthspan

Tornado is developing structural analogues of rapamycin with novel selectivity profiles that are predicted to improve safety and efficacy. The most advanced asset is now moving into IND enabling studies, while a second asset is undergoing preclinical efficacy testing.

See pipeline